Mutations in RUNX1, again commonly observed in paediatric and adult AML, correlated with sensitivity to PIK3C and mTOR inhibitors (such as BEZ235) and to the multikinase vascular endothelial growth factor receptor (VEGFR) inhibitor, cediranib. This evidence concerns the gene RUNX1 and acute myeloid leukemia.